New drug aims to boost red blood cells after transplant
NCT ID NCT07636486
First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for blood transfusions and improves hemoglobin levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Luspatercept
What this could lead to
If it works, this could offer a more effective treatment for poor red blood cell recovery after stem cell transplant, reducing the need for transfusions.
What could go wrong
This is a Phase 2/3 trial with only 90 participants, so results may not apply broadly. Luspatercept may not work better than epoetin, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.